JPWO2019185515A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019185515A5 JPWO2019185515A5 JP2021501084A JP2021501084A JPWO2019185515A5 JP WO2019185515 A5 JPWO2019185515 A5 JP WO2019185515A5 JP 2021501084 A JP2021501084 A JP 2021501084A JP 2021501084 A JP2021501084 A JP 2021501084A JP WO2019185515 A5 JPWO2019185515 A5 JP WO2019185515A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- protein
- biomarker protein
- fucα1
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims 49
- 108090000623 proteins and genes Proteins 0.000 claims 49
- 102000004965 antibodies Human genes 0.000 claims 23
- 108090001123 antibodies Proteins 0.000 claims 23
- 239000000107 tumor biomarker Substances 0.000 claims 21
- 239000000090 biomarker Substances 0.000 claims 16
- 235000000346 sugar Nutrition 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 11
- 102000038129 antigens Human genes 0.000 claims 11
- 108091007172 antigens Proteins 0.000 claims 11
- 239000002523 lectin Substances 0.000 claims 11
- 206010003816 Autoimmune disease Diseases 0.000 claims 10
- 102000004856 Lectins Human genes 0.000 claims 10
- 108090001090 Lectins Proteins 0.000 claims 10
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 10
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 10
- 200000000018 inflammatory disease Diseases 0.000 claims 9
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 150000004676 glycans Chemical class 0.000 claims 4
- 125000005630 sialyl group Chemical group 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 3
- SQVRNKJHWKZAKO-YRMXFSIDSA-N N-Acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-YRMXFSIDSA-N 0.000 claims 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 108010081954 galacto-N-biose Proteins 0.000 claims 2
- CMQZRJBJDCVIEY-JEOLMMCMSA-N α-L-Fucp-(1->3)-[β-D-Galp-(1->4)]-β-D-GlcpNAc-(1->4)-β-D-Galp-(1->3)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 claims 2
- DUKURNFHYQXCJG-JEOLMMCMSA-N α-L-Fucp-(1->4)-[β-D-Galp-(1->3)]-β-D-GlcpNAc-(1->3)-β-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 claims 2
- YGEHCIVVZVBCLE-FSYGUOKUSA-N (2R,3S,4S,5R)-2,4,5,6-tetrahydroxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound OC[C@@H](O)[C@H](O)[C@@H]([C@@H](O)C=O)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YGEHCIVVZVBCLE-FSYGUOKUSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 229940088598 Enzyme Drugs 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 101700016449 GLA Proteins 0.000 claims 1
- -1 Gal-GlcNAc Chemical compound 0.000 claims 1
- QIGJYVCQYDKYDW-SDOYDPJRSA-N Galactose-α-1,3-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 101710015954 HVA1 Proteins 0.000 claims 1
- 101700065814 LEA2 Proteins 0.000 claims 1
- 101700021338 LEC Proteins 0.000 claims 1
- 101700077545 LECC Proteins 0.000 claims 1
- 101700028499 LECG Proteins 0.000 claims 1
- 101700063913 LECT Proteins 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-ACETYL-D-GALACTOSAMINE Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 claims 1
- 101710034340 Os04g0173800 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 229940072417 Peroxidase Drugs 0.000 claims 1
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 108090000437 Peroxidases Proteins 0.000 claims 1
- XBSNXOHQOTUENA-KRAHZTDDSA-N Sialyl-Lewis A Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)C(O)O[C@@H]1CO XBSNXOHQOTUENA-KRAHZTDDSA-N 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims 1
- 102000025417 antigen binding proteins Human genes 0.000 claims 1
- 108091000829 antigen binding proteins Proteins 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 102000034387 fluorescent proteins Human genes 0.000 claims 1
- 108091006031 fluorescent proteins Proteins 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 101700036391 lecA Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 101700001016 mbhA Proteins 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Polymers 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N α-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-SXUWKVJYSA-N α-L-fucose Chemical compound C[C@@H]1O[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-SXUWKVJYSA-N 0.000 claims 1
- NIGUVXFURDGQKZ-KRAHZTDDSA-N α-Neup5Ac-(2->3)-β-D-Galp-(1->4)-[α-L-Fucp-(1->3)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-KRAHZTDDSA-N 0.000 claims 1
- CDOJPCSDOXYJJF-CAQKAZPESA-N β-D-GalpNAc-(1->4)-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 CDOJPCSDOXYJJF-CAQKAZPESA-N 0.000 claims 1
Claims (21)
（ａ）前記タンパク質を含むサンプルを、前記タンパク質に対する抗体に接触させて、抗体－タンパク質複合体を形成するステップと、
（ｂ）ステップ（ａ）で得た前記抗体－タンパク質複合体を単離するステップと、
（ｃ）その後、前記抗体－タンパク質複合体を１つ以上のレクチンに接触させて、前記タンパク質の糖鎖プロファイルを判定するステップとを含み、
ステップ（ａ）の前記抗体は固体表面上に固定化されておらず、前記タンパク質は、該方法を行っているとき、前記抗体から放出されない、方法。 A method for determining the sugar chain profile of a protein.
(A) A step of contacting a sample containing the protein with an antibody against the protein to form an antibody-protein complex.
(B) The step of isolating the antibody-protein complex obtained in step (a) and
(C) The step comprising contacting the antibody-protein complex with one or more lectins to determine the sugar chain profile of the protein.
The method, wherein the antibody of step (a) is not immobilized on a solid surface and the protein is not released from the antibody when performing the method.
（ａ）前記対象から得た、がんバイオマーカータンパク質を含むサンプルを、前記がんバイオマーカータンパク質に対する抗体に接触させて、抗体－がんバイオマーカータンパク質複合体を形成するステップと、
（ｂ）ステップ（ａ）で得た前記抗体－タンパク質複合体を単離するステップと、
（ｃ）その後、前記抗体－がんバイオマーカータンパク質複合体を１つ以上のレクチンに接触させて、前記がんバイオマーカータンパク質の糖鎖プロファイルを判定するステップとを含み、
ステップ（ａ）の前記抗体は固体表面上に固定化されておらず、前記タンパク質は、該方法を行っているとき、前記抗体から放出されず、
前記糖鎖プロファイルの、前記がんバイオマーカータンパク質の健常な糖鎖プロファイルからのずれは、前記対象ががんのリスクを有し得る、又はがんに罹患し得ることを示す、方法。 A method of diagnosing that a subject may be at risk of cancer or may have cancer.
(A) A step of contacting a sample containing a cancer biomarker protein obtained from the subject with an antibody against the cancer biomarker protein to form an antibody-cancer biomarker protein complex.
(B) The step of isolating the antibody-protein complex obtained in step (a) and
(C) The step comprising contacting the antibody-cancer biomarker protein complex with one or more lectins to determine the sugar chain profile of the cancer biomarker protein.
The antibody of step (a) was not immobilized on a solid surface and the protein was not released from the antibody when performing the method.
A method of indicating that a deviation of the sugar chain profile from a healthy sugar chain profile of the cancer biomarker protein indicates that the subject may be at risk of cancer or may suffer from cancer.
（ａ）前記対象から得た、自己免疫性疾患バイオマーカータンパク質を含むサンプルを、前記自己免疫性疾患バイオマーカータンパク質に対する抗体に接触させて、抗体－自己免疫性疾患バイオマーカータンパク質複合体を形成するステップと、
（ｂ）ステップ（ａ）で得た前記抗体－タンパク質複合体を単離するステップと、
（ｃ）その後、前記抗体－自己免疫性疾患バイオマーカータンパク質複合体を１つ以上のレクチンに接触させて、前記自己免疫性疾患バイオマーカータンパク質の糖鎖プロファイルを判定するステップとを含み、
ステップ（ａ）の前記抗体は固体表面上に固定化されておらず、前記タンパク質は、該方法を行っているとき、前記抗体から放出されず、
前記糖鎖プロファイルの、前記自己免疫性疾患バイオマーカータンパク質の健常な糖鎖プロファイルからのずれは、前記対象が自己免疫性疾患のリスクを有し得る、又は自己免疫性疾患に罹患し得ることを示す、方法。 A method of diagnosing that a subject may be at risk for an autoimmune disease or may suffer from an autoimmune disease.
(A) A sample containing an autoimmune disease biomarker protein obtained from the subject is contacted with an antibody against the autoimmune disease biomarker protein to form an antibody-autoimmune disease biomarker protein complex. Steps and
(B) The step of isolating the antibody-protein complex obtained in step (a) and
(C) The step comprising contacting the antibody-autoimmune disease biomarker protein complex with one or more lectins to determine the sugar chain profile of the autoimmune disease biomarker protein.
The antibody of step (a) was not immobilized on a solid surface and the protein was not released from the antibody when performing the method.
Deviations of the glycan profile from the healthy glycan profile of the autoimmune disease biomarker protein indicate that the subject may be at risk for autoimmune disease or may suffer from autoimmune disease. Show, how.
（ａ）前記対象から得た、炎症性疾患バイオマーカータンパク質を含むサンプルを、前記炎症性疾患バイオマーカータンパク質に対する抗体に接触させて、抗体－炎症性疾患バイオマーカータンパク質複合体を形成するステップと、
（ｂ）ステップ（ａ）で得た前記抗体－タンパク質複合体を単離するステップと、
（ｃ）その後、前記抗体－炎症性疾患バイオマーカータンパク質複合体を１つ以上のレクチンに接触させて、前記炎症性疾患バイオマーカータンパク質の糖鎖プロファイルを判定するステップとを含み、
ステップ（ａ）の前記抗体は固体表面上に固定化されておらず、前記タンパク質は、該方法を行っているとき、前記抗体から放出されず、
前記糖鎖プロファイルの、前記炎症性疾患バイオマーカータンパク質の健常な糖鎖プロファイルからのずれは、前記対象が炎症性疾患のリスクを有し得る、又は炎症性疾患に罹患し得ることを示す、方法。 A method of diagnosing that a subject may be at risk of or suffering from an inflammatory disease.
(A) A step of contacting a sample containing the inflammatory disease biomarker protein obtained from the subject with an antibody against the inflammatory disease biomarker protein to form an antibody-inflammatory disease biomarker protein complex.
(B) The step of isolating the antibody-protein complex obtained in step (a) and
(C) The step comprising contacting the antibody-inflammatory disease biomarker protein complex with one or more lectins to determine the sugar chain profile of the inflammatory disease biomarker protein.
The antibody of step (a) was not immobilized on a solid surface and the protein was not released from the antibody when performing the method.
A method of indicating that a deviation of the glycan profile from a healthy glycan profile of the inflammatory disease biomarker protein indicates that the subject may be at risk of inflammatory disease or may suffer from inflammatory disease. ..
前記磁性担体は、ペルオキシダーゼ活性を有するポリペプチドを含む、請求項１～１０及び１４～１９のいずれか１項に記載の方法。The method according to any one of claims 1 to 10 and 14 to 19, wherein the magnetic carrier contains a polypeptide having peroxidase activity.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18163899.0 | 2018-03-26 | ||
| EP18163899 | 2018-03-26 | ||
| PCT/EP2019/057386 WO2019185515A1 (en) | 2018-03-26 | 2019-03-25 | Means and methods for glycoprofiling of a protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519443A JP2021519443A (en) | 2021-08-10 |
| JPWO2019185515A5 true JPWO2019185515A5 (en) | 2022-04-01 |
Family
ID=61800357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021501084A Pending JP2021519443A (en) | 2018-03-26 | 2019-03-25 | Means and methods of protein sugar chain profiling |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20210048437A1 (en) |
| EP (2) | EP3775909B1 (en) |
| JP (1) | JP2021519443A (en) |
| KR (1) | KR20200138300A (en) |
| AU (1) | AU2019246007A1 (en) |
| CA (1) | CA3091733A1 (en) |
| DK (1) | DK3775909T3 (en) |
| ES (1) | ES2950740T3 (en) |
| FI (1) | FI3775909T3 (en) |
| HR (1) | HRP20230744T1 (en) |
| HU (1) | HUE062414T2 (en) |
| IL (1) | IL277194A (en) |
| LT (1) | LT3775909T (en) |
| PL (1) | PL3775909T3 (en) |
| PT (1) | PT3775909T (en) |
| RS (1) | RS64431B1 (en) |
| SI (1) | SI3775909T1 (en) |
| WO (1) | WO2019185515A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111208304B (en) * | 2020-01-20 | 2023-06-16 | 中国医学科学院北京协和医院 | Use of tumor-derived IgG in diagnosis and prognosis of parathyroid cancer |
| CN113009130B (en) * | 2021-02-10 | 2022-08-23 | 中国医学科学院北京协和医院 | Biomarker for diagnosing primary sicca syndrome and application thereof |
| CN113009131B (en) * | 2021-02-10 | 2022-08-23 | 中国医学科学院北京协和医院 | Biomarker for diagnosing primary sicca syndrome and application thereof |
| WO2022186317A1 (en) * | 2021-03-03 | 2022-09-09 | 株式会社先端生命科学研究所 | Cancer detection method, cancer examination method, and kit using same |
| CA3228163A1 (en) | 2021-08-06 | 2023-02-09 | Jan Tkac | Standard for glycoprofiling of proteins |
| CN113702637B (en) * | 2021-08-09 | 2023-04-07 | 西北大学 | Lectin test carrier, kit and prediction model for predicting neoadjuvant chemotherapy curative effect of breast cancer |
| CN113721029B (en) * | 2021-08-25 | 2023-06-06 | 西北大学 | Testing tool and system for identifying liver cirrhosis and liver cancer by specific lectin combination |
| KR20240043818A (en) | 2021-08-26 | 2024-04-03 | 글리카노스틱스 에스.알.오. | Glycoprotein biomarkers for cancer diagnosis |
| KR20240053007A (en) | 2021-09-14 | 2024-04-23 | 글리카노스틱스 에스.알.오. | Glycoprotein biomarkers for breast cancer diagnosis |
| WO2023198337A1 (en) | 2022-04-12 | 2023-10-19 | Glycanostics S.R.O. | Means and methods for high-throughput glycoprofiling of proteins |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816A (en) | 1846-10-17 | Bell machinery for hotels | ||
| US4676A (en) | 1846-07-31 | roller | ||
| US567A (en) | 1838-01-09 | Machine for r-uibbii | ||
| US980A (en) | 1838-10-13 | Improvement in the mode of hardening or chilling the hubs of car and other wheels | ||
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | Modifications of or for denatured antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (en) | 1988-09-02 | 1998-01-02 | Dyax Corp | Production and selection of recombinant proteins with different binding sites |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (en) | 1990-07-10 | 2000-02-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS. |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech Inc | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ES2315612T3 (en) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | GENOTECAS OF HETERODYMERIC RECEPTORS USING PHAGEMIDS. |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0859841T3 (en) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein / (poly) peptide libraries |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| CN1202128C (en) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | Method for reducing immunogenicity of proteins |
| US7838634B2 (en) * | 2005-04-15 | 2010-11-23 | Van Andel Research Institute | Methods for measuring glycan levels of proteins |
| JP4711190B2 (en) * | 2006-07-28 | 2011-06-29 | 国立大学法人 東京大学 | Test method for glycosylation disorder |
| US9169327B2 (en) | 2008-03-12 | 2015-10-27 | Rowan University | Targeting of podoplanin with lectin for use in the prevention and treatment of cancer |
| JP2011529184A (en) * | 2008-07-25 | 2011-12-01 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Detection of prostate cancer using PSA glycosylation pattern |
| JP2010091308A (en) * | 2008-10-04 | 2010-04-22 | Sapporo Medical Univ | Method for diagnosing prostate carcinoma by lectin absorbing method and prostate carcinoma determining kit |
-
2019
- 2019-03-25 AU AU2019246007A patent/AU2019246007A1/en active Pending
- 2019-03-25 HR HRP20230744TT patent/HRP20230744T1/en unknown
- 2019-03-25 JP JP2021501084A patent/JP2021519443A/en active Pending
- 2019-03-25 HU HUE19718572A patent/HUE062414T2/en unknown
- 2019-03-25 LT LTEPPCT/EP2019/057386T patent/LT3775909T/en unknown
- 2019-03-25 KR KR1020207030659A patent/KR20200138300A/en not_active Application Discontinuation
- 2019-03-25 US US17/041,816 patent/US20210048437A1/en active Pending
- 2019-03-25 WO PCT/EP2019/057386 patent/WO2019185515A1/en unknown
- 2019-03-25 ES ES19718572T patent/ES2950740T3/en active Active
- 2019-03-25 EP EP19718572.1A patent/EP3775909B1/en active Active
- 2019-03-25 FI FIEP19718572.1T patent/FI3775909T3/en active
- 2019-03-25 DK DK19718572.1T patent/DK3775909T3/en active
- 2019-03-25 EP EP23172000.4A patent/EP4253958A3/en active Pending
- 2019-03-25 PL PL19718572.1T patent/PL3775909T3/en unknown
- 2019-03-25 PT PT197185721T patent/PT3775909T/en unknown
- 2019-03-25 CA CA3091733A patent/CA3091733A1/en active Pending
- 2019-03-25 SI SI201930572T patent/SI3775909T1/en unknown
- 2019-03-25 RS RS20230533A patent/RS64431B1/en unknown
-
2020
- 2020-09-07 IL IL277194A patent/IL277194A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230744T1 (en) | Means and methods for glycoprofiling of a protein | |
| Zhao et al. | Glycan analysis of colorectal cancer samples reveals stage-dependent changes in CEA glycosylation patterns | |
| Drake et al. | Sweetening the pot: adding glycosylation to the biomarker discovery equation | |
| Tkac et al. | Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer | |
| Connelly et al. | Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer | |
| Meany et al. | Aberrant glycosylation associated with enzymes as cancer biomarkers | |
| Vermassen et al. | Glycosylation of prostate specific antigen and its potential diagnostic applications | |
| EP2174132A2 (en) | Glycosylation markers for cancer and chronic inflammation | |
| JP4711190B2 (en) | Test method for glycosylation disorder | |
| JPWO2019185515A5 (en) | ||
| Terävä et al. | Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma | |
| JP2011529184A (en) | Detection of prostate cancer using PSA glycosylation pattern | |
| CN102317785A (en) | Method for analyzing psa, and method for distinguishing between prostate cancer and prostatomegaly employing the analysis method | |
| Park et al. | N‐glycosylation status of β‐haptoglobin in sera of patients with colon cancer, chronic inflammatory diseases and normal subjects | |
| JP6880033B2 (en) | Glycosylation signature determination | |
| Pochechueva et al. | Blood plasma-derived anti-glycan antibodies to sialylated and sulfated glycans identify ovarian cancer patients | |
| Grün et al. | One-step biotinylation procedure for carbohydrates to study carbohydrate–protein interactions | |
| EP3485278B1 (en) | Lectin-based diagnostics of cancers | |
| Kam et al. | The potentials of glycomics in biomarker discovery | |
| CN103748466A (en) | Method for analyzing mucin 1 using probe capable of binding to 3'-sulfonated core 1 carbohydrate chain, and method for detecting or monitoring breast cancer | |
| US20080293147A1 (en) | Method of Detecting Structural Change in Target Sugar Chain | |
| JP2019011978A (en) | Method and kit for measuring the amount of fucosyl sugar chain in glycoprotein | |
| KR20240035629A (en) | Standards for sugar profiling of proteins | |
| US8580491B2 (en) | Cancer diagnosis marker using the aberrant glycosylation of a protein | |
| US20120258471A1 (en) | Peptide marker for cancer diagnosis, and cancer diagnosis method using same |